anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Conventional dendritic cells (DCs) are essential mediators of antitumor immunity. As a result, cancers have developed poorly understood mechanisms to render DCs dysfunctional within the tumor microenvironment (TME). After identification of CD63 as a specific surface marker, we demonstrate that mature regulatory DCs (mregDCs) migrate to tumor-draining lymph node tissues and suppress DC antigen cross-presentation in trans while promoting T helper 2 and regulatory T cell differentiation. Transcriptional and metabolic studies showed that mregDC functionality is dependent on the mevalonate biosynthetic pathway and its master transcription factor, SREBP2. We found that melanoma-derived lactate activates SREBP2 in tumor DCs and drives conventional DC transformation into mregDCs via homeostatic or tolerogenic maturation. DC-specific genetic silencing and pharmacologic inhibition of SREBP2 promoted antitumor CD8+ T cell activation and suppressed melanoma progression. CD63+ mregDCs were found to reside within the lymph nodes of several preclinical tumor models and in the sentinel lymph nodes of patients with melanoma. Collectively, this work suggests that a tumor lactate-stimulated SREBP2-dependent program promotes CD63+ mregDC development and function while serving as a promising therapeutic target for overcoming immune tolerance in the TME.
PURPOSE:To provide the title composition having high detergent effect on the makeup stain due to cosmetics resistant to malmakeup, also favorable in the touch in washing therewith, containing, as the main ingredient, a specific low- molecular weight polyether-modified silicone. CONSTITUTION:The objective composition containing a polyether-modified silicone <=3500 in molecular weight, e.g. a compound of formula I (R1 is methyl or phenyl; p is 0-9 on average; g is 1-5 on average; r is 0 or 1; X1-X3 are each methyl, phenyl, etc.) [in particular, pref. of formula II (a is 1-16 on average; b is 0-12 on average ; c is 1-6; a+b>=1)]. The present composition gives high detergency in a short time on makeup stain due to rouge, foundation, etc., and on oily stain such as of sebum, also being favorable in the touch during or after washing therewith.
PROBLEM TO BE SOLVED: To obtain an activated poly-L-glutamic acid having a long activity retention time by reacting a poly-L-glutamic acid wherein a specified proportion of the carboxyl groups are in the form of an active ester with an N-hydroxyamine ester derivative compound. SOLUTION: A poly-L-glutamic acid is dissolved in a polar solvent and a specified amount of an N-hydroxyamine type active ester derivative compound (e.g. N- hydroxysuccinimide) and a dehydratively condensing agent (e.g. 1-ethyl-3- dimethylaminopropylcarbodiimide hydrochloride) are added to the solution. After the entire mixture is shaken at about 0-40 deg.C for 3-24hr to effect a reaction, the product is washed and dried to obtain an activated poly-L-glutamic acid wherein 35-70% of the carboxyl groups are in the form an active ester.  Next, a buffer solution obtained by dissolving gelatin having a spontaneous gelation temperature of 20-25 deg.C, used in such an amount as to give a concentration of about 50 to 500mg/ml and having a pH of 7.0-7.6 is mixed with another buffer solution obtained by dissolving about 5 to 100mg/ml of the activated poly-L-glutamic acid and having a pH of 7.4-7.6 to obtain a mixture usable as a hemostatic or medical bonding kit.
Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
Early detection and diagnosis of pulmonary nodules is clinically significant regarding optimal treatment selection and avoidance of unnecessary surgical procedures. Deferential pathology results causes widely different prognosis after standard surgery among pulmonary precancerous lesion, atypical adenomatous hyperplasia (AAH) as well as adenocarcinoma in situ (AIS), and early stage invasive adenocarcinoma (IAC). The micro-invasion of pulmonary perifocal interstitium is difficult to identify from AIS unless pathology immunohistochemical study was implemented after operation，which may causes prolonged procedure time and inappropriate surgical decision-making. Key feature-derived variables screened from CT scans via statistics and machine learning algorithms, could form a radiomics signature for disease diagnosis, tumor staging, therapy response adn patient prognosis. The purpose of this study was to investigate whether the combined radiomic signature based on the focal and perifocal（5mm）radiomic features can effectively improve predictive performance of distinguishing precancerous lesions from early stage lung adenocarcinoma. Besides, immunotherapy response is various among patients and no more than 20% of patients could benefit from it. None reliable biomarker has been found yet expect Programmed death-ligand 1 (PD-L1) expression, the only approved biomarker for immunotherapy. However recent reports suggested that patients could benefit from immunotherapy regardless of PD-L1 positive or negative. On the contrast, radiomics has show it advantages of non-invasiveness, easy-acquired and no limitation of sampling. Therefore, we applied this strategy in prediction for the immunotherapy response of advanced NSCLC lung cancer patients receiving immune checkpoint inhibitors (ICIs), which would prevent some non-benefit patient from the adverse effect of ICIs.
Antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in pediatric patients. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.

If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac. 

If patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children. 

When life threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response, and recurrence after response. (See package circulars for physostigmine products.)

Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content. Stimulants should not be used.

Vasopressors may be used to treat hypotension.

The oral LD 50 of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.
FIELD: medicine. ^ SUBSTANCE: invention refers to cobalamin derivatives of the formula , where Rb means spacer chelating group of the formula , where n is 2, 3 or 4; Rc, Rd, Re and RR denote hydrogen, and X is cyano; or where Rd indicates spacer chelating group of the formula , where n is 3; Rb, Rc, Re, and RR denote hydrogen, and X is cyano, or where Rb indicates spacer chelating group of the formula , where n is equal to 2; Rc, Rd, Re and RR denote hydrogen, and X is cyano. These compounds are accumulated to a much lesser extent in blood and non-malignant organs such as kidneys and liver, compared with the rate of accumulation in neoplastic tissues, and moreover they are quickly removed from blood. The invention also refers to injectable pharmaceutical composition for diagnosis of tumors including cobalamin derivative carrying a radioactive metal atom. In addition, the invention refers to diagnosis of tumors in mammals, including (a) compliance vitamin B12-free diet for mammals predisposed to neoplastic disease, (b) subsequent administration of cobalamin derivative carrying a radioactive metal atom. The invention also refers to use of cobalamin derivative carrying a radioactive metal atom, in method of diagnosis of tumors in mammals and to obtain pharmaceutical composition designed for use in method of diagnosis of neoplastic diseases in mammals. ^ EFFECT: improvement of composition application. ^ 13 cl, 2 tbl, 6 dwg, 35 ex
A system for measuring long-distance respiration rate is provided. The system includes a processing unit configured to receive and normalized a sensor output signal. The processing unit is further configured to compute a series of four Discrete Prolate Spheroid window functions. For each of the series of four Discrete Prolate Spheroid window functions, the processing unit is configured to (1) multiply the normalized sensor output signal by the Discrete Prolate Spheroid window function to produce a windowed output signal, and (2) compute a Lomb-Scargle periodogram based on the windowed output signal. The processing unit is further configured to compute a weighted average of the Lomb-Scargle periodograms to produce an averaged periodogram. The processing unit is further configured to compute a frequency corresponding to a peak estimated spectral density on the averaged periodogram. The processing unit is further configured to output breaths per minute data based on the frequency.
Erythrocytes play a fundamental role in oxygen delivery to tissues and binding to inflammatory mediators. Evidences suggest that dysregulated erythrocyte function could contribute to the pathophysiology of several neurodegenerative diseases. We aimed to evaluate changes in morphological, biomechanical, and biophysical properties of erythrocytes from amyotrophic lateral sclerosis (ALS) patients, as new areas of study in this disease. Blood samples were collected from ALS patients, comparing with healthy volunteers. Erythrocytes were assessed using atomic force microscopy (AFM) and zeta potential analysis. The patients' motor and respiratory functions were evaluated using the revised ALS Functional Rating Scale (ALSFRS-R) and percentage of forced vital capacity (%FVC). Patient survival was also assessed. Erythrocyte surface roughness was significantly smoother in ALS patients, and this parameter was a predictor of faster decline in ALSFRS-R scores. ALS patients exhibited higher erythrocyte stiffness, as indicated by reduced AFM tip penetration depth, which predicted a faster ALSFRS-R score and respiratory subscore decay. A lower negative charge on the erythrocyte membrane was predictor of a faster ALSFRS-R and FVC decline. Additionally, a larger erythrocyte surface area was an independent predictor of lower survival. These changes in morphological and biophysical membrane properties of ALS patients' erythrocytes, lead to increased cell stiffness and morphological variations. We speculate that these changes might precipitate motoneurons dysfunction and accelerate disease progression. Further studies should explore the molecular alterations related to these observations. Our findings may contribute to dissect the complex interplay between respiratory function, tissue hypoxia, progression rate, and survival in ALS.
Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
Lindane exerts its parasiticidal action by being directly absorbed into the parasites and their ova. Feldmann and Maibach1 reported approximately 10% absorption of a lindane acetone solution applied to the forearm of human subjects and left in place for 24 hours. This vehicle was different from the approved product and the percutaneous penetration of lindane is dependent on the vehicle. Therefore, the clinical significance of these observations is unknown. Dale, et al2 reported a blood level of 290 ng/mL associated with convulsions following the accidental ingestion of a lindane-containing product. Ginsburg3 found a mean peak blood level of 28 ng/mL 6 hours after total body application of Lindane Lotion to scabietic infants and children. The half-life in blood was determined to be 18 hours.

Data available in the literature suggest that lindane has a rapid distribution phase followed by a longer β-elimination phase.1,2,3

There are no clinical dose ranging studies for Lindane Shampoo.
The present invention provides an anti-hepatoma gene medicine composition which comprises effective dose of safe anti-sense fup1 genes and/or small molecule interference RNA and acceptable adjuvant in pharmacy, wherein the anti-sense fup1 genes have DNA sequences shown in SEQIDNO. 2 in the sequence table, and the small molecule interference RNA comprises RNA sequences shown in SEQIDNO. 3 in the sequence table. The present invention also provides a method for sieving anti-hepatoma gene medicines of the small molecule interference RNA designed for the coding region of fup1 by RNAi design software provided by the ambion website. The present invention further provides an anti-hepatoma small molecule comprising the RNA sequences shown in SEQIDNO. 3 in the sequence table. The present invention uses high-expression genes fup1 in hepatoma cells as medicine targets, designs antagonistic molecules according to the gene sequences, provides powerful weapons for the gene therapy of hepatoma, and provides a favorable sieving platform for further sieving anti-hepatoma gene medicines.
The present invention provides a synbiotic combination of i) a probiotic micro-organism comprising of a  Lactobacillus  strain, and ii) a catechin component comprising EGCG that acts as a second generation synbiotic with synergistic effects in improving the immune response and antioxidant capacity during aging that may beneficially affect the health of elderly. The catechin fraction exhibited differential effects on growth of bacteria with strong inhibition of pathogenic bacteria as opposed to probiotic bacteria suggesting its prebiotic efficacy. In vitro testing indicated protective effects of catechin and probiotics in a synergistic manner resulting in amelioration of oxidative and inflammatory stress. In vivo analysis in aging animals further indicated that the synbiotic combination could rejuvenate the aging immune system by enhancing cellular immune response with increase in numbers (CD3+ T cells) as well as activation status of cellular immune cells (CD3+ T cells/neutrophils) along with their functional capacity (Th1/Th2 immune response) coupled with a corresponding decrease in humoral immune response (IgA) in intestine suggesting the impact of synbiotics in activating cellular immunity. Further, total antioxidant capacity (in plasma) increased in synbiotic fed animals with increased Nrf2 expression while no unwarranted exacerbation of inflammation (NfkB expression) was observed in liver extracts. Several of the observed effects showed synergism wherein the effect of synbiotics was more pronounced than pure additive effects of individual components. Together, it appears that this novel synbiotic formulation could significantly impact aging physiology and help ameliorate some of the deleterious effects during aging.
Exemplary embodiments provides computer-implemented methods, mediums, and apparatuses configured to monitor the health of analytical chemistry systems. A monitoring system may be highly coupled to laboratory analytical instruments that it monitors. It may receive data and/or trends in the data as that data is generated by the instrument. Consequently, it can be configured to recognize when that data or trend signals a problem that needs to be corrected. A kiosk of the monitoring system may be configured to be in direct communication with the analytical chemistry system and to execute an action from the issue resolution structure to make the adjustment. Because the monitoring system is part of the direct physical control of the instrument(s), it can fix problems very quickly.
Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic disorder accounting for approximately 5% of patients with renal failure, yet therapeutics for the treatment of ADPKD remain limited. ADPKD tissues display abnormalities in the biogenesis of the centrosome, a defect that can cause genome instability, aberrant ciliary signaling, and secretion of pro-inflammatory factors. Cystic cells form excess centrosomes via a process termed centrosome amplification (CA), which causes abnormal multipolar spindle configurations, mitotic catastrophe, and reduced cell viability. However, cells with CA can suppress multipolarity via "centrosome clustering," a key mechanism by which cells circumvent apoptosis. Here, we demonstrate that inhibiting centrosome clustering can counteract the proliferation of renal cystic cells with high incidences of CA. Using ADPKD human cells and mouse models, we show that preventing centrosome clustering with 2 inhibitors, CCB02 and PJ34, blocks cyst initiation and growth in vitro and in vivo. Inhibiting centrosome clustering activates a p53-mediated surveillance mechanism leading to apoptosis, reduced cyst expansion, decreased interstitial fibrosis, and improved kidney function. Transcriptional analysis of kidneys from treated mice identified pro-inflammatory signaling pathways implicated in CA-mediated cystogenesis and fibrosis. Our results demonstrate that centrosome clustering is a cyst-selective target for the improvement of renal morphology and function in ADPKD.
This group received routine physical therapy along with breathing exercises. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, neck isometrics and stretching that includes 12 sessions (3 sessions per week).
Breast cancer is the commonest cancer in female worldwide and breast-conserving surgery (BCS) became the most frequently performed surgical treatment for women with early-stage breast cancer. The ability to identify subclinical and deep-seated tumor during BCS is still difficult, and the surgeon must rely on nonspecific visual changes and manual palpation of subtle irregularities to guide cancer excision. Although there is no consensus on negative surgical margins, at least 20 % of patients undergo more than one procedure to achieve acceptable margins as part of breast-conserving strategy. The development of reliable intraoperative assessment tools which can provide a timely indication of whether re-excision in tumor bed after BCS is indicated at the time of primary surgery would be an asset. The Histolog Scanner is a recent confocal microscope designed for fresh tissue ex-vivo medical imaging with high resolution and speed to guide intraoperative assessment and offer support in clinical decision making. Allowing the quickest and most effective intraoperative assessment of breast surgical specimen regardless of center clinical workflow and intraoperative availability of pathologist, is the aim of this international study. The main objective is to demonstrate that both pathologists and surgeons are able to detect breast cancer tissues in Histolog Scanner images of breast surgical specimens.

Fresh Breast surgical specimens with breast cancer (invasive or in-situ) will be imaged with the Histolog Scanner prior Standard-of-Care final assessment in pathology. Content of the images will be reviewed by a board of expert pathologists using the gold standard (H\&E-stained images) as reference. Blind assessment of the breast cancer content of these Histolog Scanner images will be realized by breast surgeons and pathologist.
The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
This is an open label (no placebo), uncontrolled (all patients will receive TMC114 with ritonavir at the same dose, trial to investigate the sustained anti-viral activity of TMC114/rtv monotherapy in 24 treatment naïve, HIV 1 infected patients over a period of 48 weeks.TMC114, 800 mg daily (2 tablets of 400 mg \[F021\]) will be given together with 1 capsule (100 mg) of ritonavir.Initially 11 subjects (Panel A, screening viral load between 10000 and 100000 copies/mL) will be included and followed for 8 weeks. If after 8 weeks of dosing at least 7 subjects virologically respond (viral load \<400 copies/mL), 13 additional patients (Panel B) will be included. If no virologic failure is observed in at least 18 out of 24 patients who complete 8 weeks of dosing, the trial will continue as planned. In case more than 6 patients in Panel A and Panel B develop a virologic failure after 8 weeks of treatment, the trial will be stopped to conclude the treatment is not effective.The 13 additional patients enrolled in Panel B should have a screening viral load between 20000 and 500000 copies/mL. The CD4+ cell count in all 24 patients should be \> 100 cells/µL at screening. The patient's medical condition, adverse events (side effects), study medication compliance, and laboratory evaluations for effectiveness and safety will be assessed at regular intervals. At the end of the 48 weeks treatment period patients will be followed for an additional 4 weeks to evaluate any side effects or laboratory abnormalities. Treatment with TMC114/rtv will be extended for all patients who continue to benefit after 48 weeks. 2 oral tablets of TMC114 400 mg will be administered once daily with 1 capsule (100mg) of ritonavir for 48 weeks.
PROBLEM TO BE SOLVED: To improve the yield of capsules and to easily control the structure of capsules such as thickness of the capsule wall by suppressing gelation inside or outside of capsules due to excessive polymn. of radical polymerizable monomers as the wall material. SOLUTION: By this method, microcapsules containing a dispersion material inside are produced by adding radical polymerizable monomers to the dispersion system of the inner material of capsules and effecting radical polymn. of the monomers. In this method, a redox initiator system by the combination of water- insoluble oxidant/water-soluble reducing agent or a water-soluble oxidant/water- insoluble reducing agent is used to initiate the polymn. reaction to produce microcapsules.
Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.